Aptevo Therapeutics Inc.
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -345.00K | 54.00K | 49.00K | 3.75M | -565.00K |
| Gross Profit | 345.00K | -54.00K | -49.00K | -3.75M | 565.00K |
| SG&A Expenses | 2.50M | 2.11M | 2.38M | 3.23M | 2.79M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 6.38M | 5.21M | 6.02M | 6.98M | 6.38M |
| Operating Income | -6.38M | -5.21M | -6.02M | -6.98M | -6.38M |
| Income Before Tax | -6.31M | -5.10M | -5.88M | -6.83M | -6.20M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.31M | -5.10M | -5.88M | -6.83M | -6.20M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | 293.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.31M | -5.10M | -5.88M | -6.83M | -5.90M |
| EBIT | -6.38M | -5.21M | -6.02M | -6.98M | -6.38M |
| EBITDA | -6.31M | -5.13M | -5.93M | -6.88M | -6.27M |
| EPS Basic | -7.73 | -17.89 | -61.84 | -368.21 | -438.43 |
| Normalized Basic EPS | -4.83 | -11.18 | -38.65 | -230.13 | -287.62 |
| EPS Diluted | -7.74 | -17.89 | -61.84 | -368.21 | -438.50 |
| Normalized Diluted EPS | -4.83 | -11.18 | -38.65 | -230.13 | -287.62 |
| Average Basic Shares Outstanding | 816.30K | 285.10K | 95.10K | 18.60K | 13.50K |
| Average Diluted Shares Outstanding | 816.30K | 285.10K | 95.10K | 18.60K | 13.50K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |